Keytruda

(Pembrolizumab)

ApprovedMonoclonal antibody

Pembrolizumab is used to treat certain types of cancer, including melanoma and lung cancer, by helping the immune system recognize and attack cancer cells.[2] Keytruda is currently approved and in use across 292 indications[4].[1]

Keytruda is one of 2200 monoclonal antibody programs targeting Cervical Cancer. It is currently in Approved.

292

Indications

2,269

Total Trials

Active Trials

2,199

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cervical CancerCompleted

Esophageal Squamous Cell CarcinomaCompleted

Intestinal CancerCompleted

Follicular LymphomaTerminated

Cutaneous Squamous Cell CarcinomaActive, not recruiting

MeningiomaActive, not recruiting

Breast CancerCompleted

Penile CancerCompleted

LymphomaCompleted

Locally Advanced or Metastatic Solid TumorsTerminated

Cervical CancerPhase 3

Completed

Esophageal Squamous Cell CarcinomaPhase 3

Completed

Intestinal CancerPhase 2

Completed

Follicular LymphomaPhase 2

Terminated

Cutaneous Squamous Cell CarcinomaPhase 3

Active, not recruiting

MeningiomaPhase 2

Active, not recruiting

Breast CancerPhase 3

Completed

Penile CancerPhase 2

Completed

LymphomaPhase 3

Completed

Locally Advanced or Metastatic Solid TumorsPhase 2

Terminated

Showing 10 of 291 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Approved

90 2

Zolymbus

AbbVie

Preclinical

1 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 4

Acupan

YYonsei University

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

Ablavar

LLantheus Medical Imaging

Preclinical

2 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pembrolizumab

NCT02717156

Phase 1Active, not recruiting

Neuroendocrine Cancer

NCT03582475

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT03774732

Phase 2Recruiting

Soft Tissue Sarcoma

NCT05679921

Phase 1/2Recruiting

Breast Cancer

NCT05491083

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT05499390

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer19 trials

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Completed·SSyndax Pharmaceuticals·Phase 1/2·NCT02437136·191 enrolled

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2/3·NCT06984588·450 enrolled

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 3·NCT06980272·420 enrolled

Show 16 more trials

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT03546361·24 enrolled

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03302234·568 enrolled

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03850444·262 enrolled

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients

Terminated·OOslo University Hospital··NCT04557007·80 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Active, not recruiting·UUNICANCER·Phase 3·NCT03774732·327 enrolled

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT05633602·838 enrolled

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Completed·YYale University·Phase 2·NCT02681549·41 enrolled

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05609968·614 enrolled

Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy

Unknown status·XXiaorong Dong·Phase 1/2·NCT04333004·40 enrolled

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting·IImperial College London·Phase 3·NCT05085028·1,750 enrolled

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03875092·125 enrolled

AK112 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting·AAkeso·Phase 3·NCT05499390·398 enrolled

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06448312·406 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03976375·422 enrolled

Breast Cancer14 trials

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Active, not recruiting·PProvidence Health & Services·Phase 1/2·NCT02734290·29 enrolled

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02755272·87 enrolled

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Withdrawn·NNorthwestern University·Phase 1·NCT05093387

Show 11 more trials

Converting HR+ Breast Cancer Into an Individualized Vaccine

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03804944·100 enrolled

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Unknown status·YYonsei University·Phase 2·NCT04946227·52 enrolled

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Completed·MMayo Clinic·Phase 1·NCT03012230·12 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Unknown status·MMediclinic Middle East·Phase 2·NCT03879174·25 enrolled

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Terminated·NNational Taiwan University Hospital·Phase 1/2·NCT02990845·16 enrolled

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

Completed·CCORTESI LAURA·Phase 2·NCT03732391·22 enrolled

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

Completed·CCentre Leon Berard·Phase 2·NCT03139851·36 enrolled

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT05491083·51 enrolled

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 1·NCT03197389·54 enrolled

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06942234·180 enrolled

Pembrolizumab13 trials

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Not yet recruiting·—·Phase 2·NCT07465276·32 enrolled

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT02717156·103 enrolled

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02595866·58 enrolled

Show 10 more trials

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Completed·HHalozyme Therapeutics·Phase 1·NCT02563548·56 enrolled

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Active, not recruiting·PPeking University·Phase 2·NCT05894889·70 enrolled

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Unknown status·SSamsung Medical Center·Phase 2·NCT03656094·98 enrolled

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Completed·BBaptist Health South Florida·Phase 2·NCT03274661·52 enrolled

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting·NNETRIS Pharma·Phase 1/2·NCT04652076·240 enrolled

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT06116578

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Recruiting·XXiaorong Dong·Phase 2·NCT05745350·45 enrolled

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Completed·CCommonwealth Healthcare Corporation··NCT07015333·31 enrolled

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Completed·YYana Najjar·Phase 1·NCT02339324·31 enrolled

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Recruiting·AARCAGY/ GINECO GROUP·Phase 2·NCT04602377·27 enrolled

Melanoma11 trials

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Completed·—··NCT03197636·40 enrolled

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01866319·834 enrolled

Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

Completed·—··NCT02909348·25 enrolled

Show 8 more trials

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT02130466·184 enrolled

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Unknown status·TTaizhou Hanzhong biomedical co. LTD·Phase 3·NCT05647954·350 enrolled

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Terminated·MMayo Clinic·Phase 1/2·NCT03325101·7 enrolled

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03200847·26 enrolled

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Terminated· Roche logo

Roche·Phase 3·NCT03273153·446 enrolled

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Unknown status·KKeio University·Phase 1/2·NCT04546074·22 enrolled

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Active, not recruiting·MMelanoma Institute Australia·Phase 2·NCT04207086·21 enrolled

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03665597·138 enrolled

Lymphoma7 trials

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Terminated·SStingthera, Inc.·Phase 1·NCT04609579·27 enrolled

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06504394·66 enrolled

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03210662·17 enrolled

Show 4 more trials

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·KKami Maddocks·Phase 1·NCT02950220·2 enrolled

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

Recruiting·NNational Cancer Centre, Singapore·Phase 2·NCT06160843·24 enrolled

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Completed·—·Phase 1/2·NCT02650999·12 enrolled

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting·UUniversity of Cologne·Phase 2·NCT04838652·29 enrolled

87 more indications

Metastatic Melanoma7 trials

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Terminated·JJohn Rieth·Phase 1/2·NCT03957551·28 enrolled

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422779·100 enrolled

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Active, not recruiting·EEvaxion Biotech A/S·Phase 2·NCT05309421·17 enrolled

Show 4 more trials

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Unknown status·IIntergruppo Melanoma Italiano·Phase 2·NCT03514901·120 enrolled

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Completed· Novartis logo

Novartis··NCT05611229·1,975 enrolled

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Completed·IInstitute of Oncology Ljubljana·N/A·NCT07436390·132 enrolled

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Completed· Incyte logo

Incyte·Phase 3·NCT02752074·706 enrolled

Small Cell Lung Cancer6 trials

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03066778·453 enrolled

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03829332·623 enrolled

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT05623319·60 enrolled

Show 3 more trials

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05224141·460 enrolled

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04725188·255 enrolled

Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

Completed·SSeoul National University Hospital·Phase 2·NCT02551432·26 enrolled

Advanced Solid Tumors5 trials

A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT05394350·27 enrolled

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Recruiting·OOncomatryx Biopharma S.L.·Phase 1·NCT05547321·150 enrolled

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT03179436·415 enrolled

Show 2 more trials

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02553499·37 enrolled

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT03099161·10 enrolled

Lung Cancer5 trials

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT05255302·1,360 enrolled

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT05692999·1,166 enrolled

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

Completed·—·N/A·NCT04793815·15 enrolled

Show 2 more trials

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04252365·20 enrolled

Pembrolizumab + Idelalisib for Lung Cancer Study

Terminated·AAsha Nayak·Phase 1/2·NCT03257722·4 enrolled

Neoadjuvant Therapy4 trials

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02690558·39 enrolled

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05980702·192 enrolled

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Completed·TTianjin Medical University Second Hospital·Phase 2·NCT05485896·23 enrolled

Show 1 more trial

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Recruiting·TTang-Du Hospital·Phase 2·NCT06006650·114 enrolled

Colorectal Cancer3 trials

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Terminated·—·Phase 2·NCT03844750·6 enrolled

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT02713373·45 enrolled

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05035381·10 enrolled

Gastric Cancer3 trials

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Recruiting·SShanghai Minimally Invasive Surgery Center·Phase 2·NCT06036745·20 enrolled

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Active, not recruiting·YYonsei University·Phase 1/2·NCT05508737·75 enrolled

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Unknown status·SSamsung Medical Center·Phase 2·NCT04632459·35 enrolled

Metastatic Cancer3 trials

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting·SSalubris Biotherapeutics Inc·Phase 1/2·NCT05620134·263 enrolled

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No longer available·NNational Institutes of Health Clinical Center (CC)··NCT04135092

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04536922

Ovarian Cancer3 trials

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT03275506·91 enrolled

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

Completed·TThe Affiliated Hospital of Qingdao University··NCT05188781·34 enrolled

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Active, not recruiting·RRobert Edwards·Phase 1/2·NCT03734692·24 enrolled

Advanced Cancers2 trials

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Completed·TTrishula Therapeutics, Inc.·Phase 1·NCT03884556·56 enrolled

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Completed·AAaron Miller·Phase 1·NCT03568058·25 enrolled

Metastatic NSCLC2 trials

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Recruiting·GGazi University··NCT07394062·400 enrolled

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Terminated·AAchilles Therapeutics UK Limited·Phase 1/2·NCT04032847·27 enrolled

Immune Checkpoint Inhibition2 trials

REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

Unknown status·UUniversity College, London·Phase 2·NCT04913025·160 enrolled

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Completed·WWake Forest University Health Sciences·Phase 2·NCT04454489·21 enrolled

Advanced NSCLC2 trials

Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03447678·65 enrolled

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06142617·37 enrolled

Head and Neck Cancer2 trials

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04847466·18 enrolled

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Terminated·AAethlon Medical Inc.·N/A·NCT04453046·2 enrolled

Renal Cell Carcinoma2 trials

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer··NCT04682587·481 enrolled

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Terminated·GGenenta Science·Phase 1/2·NCT06716853·10 enrolled

Adjuvant Treatment2 trials

Anti PD-1 Neo-adjuvant Treatment for NSCLC

Completed·JJair Bar, M.D., Ph.D.·Phase 1·NCT02938624·28 enrolled

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT07460206·108 enrolled

Bladder Cancer2 trials

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04241185·520 enrolled

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Terminated·UUniversity of Oxford·Phase 1/2·NCT03167151·6 enrolled

Glioblastoma2 trials

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

Recruiting·MMedical University of Silesia·Phase 4·NCT05235737·36 enrolled

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma

Unknown status·UUniversity of Louisville·Phase 1·NCT05700955·30 enrolled

Hepatocellular Carcinoma2 trials

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02940496·15 enrolled

Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT05389527·43 enrolled

Immunotherapy2 trials

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Terminated·CCalithera Biosciences, Inc·Phase 2·NCT04265534·40 enrolled

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

Completed·UUNICANCER·Phase 2·NCT04357873·112 enrolled

Cervical Cancer2 trials

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting·PPrecigen, Inc·Phase 2·NCT06157151·46 enrolled

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Terminated·UUniversity of South Alabama·Phase 2·NCT04230954·5 enrolled

Urothelial Carcinoma2 trials

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03464734·70 enrolled

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Recruiting·VVasgene Therapeutics, Inc·Phase 2·NCT04486781·38 enrolled

Safety and Efficacy2 trials

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Completed·CCytovation AS·Phase 1/2·NCT05383170·6 enrolled

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Terminated·AAduro Biotech, Inc.·Phase 1/2·NCT02575807·35 enrolled

Endometrial Cancer2 trials

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Completed·YYale University·Phase 2·NCT02899793·25 enrolled

Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

Completed·VVall d'Hebron Institute of Oncology·Phase 2·NCT03276013·48 enrolled

Soft Tissue Sarcoma2 trials

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Active, not recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT06128863·40 enrolled

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Recruiting·YYonsei University·Phase 2·NCT05679921·116 enrolled

Biliary Tract Cancer2 trials

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06230471·60 enrolled

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Terminated·GGenome & Company·Phase 2·NCT05998447·10 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Active, not recruiting·TTrisha Wise-Draper·Phase 2·NCT02641093·96 enrolled

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·DDynavax Technologies Corporation·Phase 1/2·NCT02521870·241 enrolled

Advanced/Metastatic Solid Tumors1 trial

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03473925·107 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT03019588·94 enrolled

Laryngeal Squamous Cell Carcinoma1 trial

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Completed·VVinita Takiar·Phase 1/2·NCT02759575·9 enrolled

Advanced Solid Cancers1 trial

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04171219·31 enrolled

Advanced Solid Malignancies1 trial

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Active, not recruiting·TTreadwell Therapeutics, Inc·Phase 1/2·NCT04521413·170 enrolled

Head and Neck Carcinoma1 trial

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Active, not recruiting·RRTOG Foundation, Inc.·Phase 2·NCT03546582·86 enrolled

Pancreatic Adenocarcinoma1 trial

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

Myelodysplastic Syndrome1 trial

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02936752·28 enrolled

Anaplastic Meningioma1 trial

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Terminated·RRabin Medical Center·Phase 2·NCT03016091·18 enrolled

Malignant Mesothelioma1 trial

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT02399371·65 enrolled

KRAS G12C1 trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04956640·540 enrolled

Liver Cancer1 trial

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Completed· Bayer logo

Bayer·Phase 2·NCT04696055·95 enrolled

Neuroendocrine Cancer1 trial

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT03582475·15 enrolled

Adenocarcinoma1 trial

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05268510·31 enrolled

Patients With Advanced Solid Tumors1 trial

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Completed·SSyndax Pharmaceuticals·Phase 1·NCT02909452·30 enrolled

Esophageal Cancer1 trial

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Terminated·AAduro Biotech, Inc.·Phase 2·NCT03122548·5 enrolled

Prospective1 trial

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Unknown status·SSichuan University··NCT03373955·60 enrolled

Advanced Urothelial Cancer1 trial

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02256436·542 enrolled

Clear Cell Renal Carcinoma1 trial

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Unknown status·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03280667·59 enrolled

Chemotherapy1 trial

Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC

Unknown status·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT04586465·23 enrolled

Brachytherapy1 trial

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Active, not recruiting·UUniversity of Cincinnati·Phase 1/2·NCT04340258·50 enrolled

Metastasis1 trial

Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

Not yet recruiting·ZZhejiang Provincial People's Hospital·Phase 2·NCT06694350·54 enrolled

Leukemia1 trial

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03514017·5 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT06276504·33 enrolled

Immune Checkpoint Inhibitor1 trial

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Withdrawn·YYale University·Phase 2·NCT04179110

Renal Medullary Carcinoma1 trial

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Recruiting·GGiuseppe Procopio·Phase 2·NCT06302569·23 enrolled

Metastatic Colorectal Cancer1 trial

Electroporation and Immunotherapy in Metastatic Colorectal Cancer

Terminated·IIsmail Gögenur·Phase 2·NCT05609656·4 enrolled

Fallopian Tube Cancer1 trial

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

Nasopharyngeal Carcinoma1 trial

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Terminated·AAtara Biotherapeutics·Phase 1/2·NCT03769467·12 enrolled

Locally Advanced1 trial

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Not yet recruiting·PProf. Dr. Remi A. Nout·Phase 2·NCT07368985·87 enrolled

Pancreatic Cancer1 trial

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

Completed·BBioLineRx, Ltd.·Phase 2·NCT02826486·80 enrolled

Neoadjuvant Treatment1 trial

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

Completed·—·Phase 2·NCT03064490·35 enrolled

Glioma1 trial

Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

Withdrawn·JJose Carrillo·Phase 1·NCT04220892

Phase 11 trial

Phase 1 First-in-human Study of JS014

Unknown status·AAnwita Biosciences·Phase 1·NCT05296772·60 enrolled

Kaposi Sarcoma1 trial

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

Withdrawn·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 2·NCT05846724

Mucosal Melanoma1 trial

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated·YYonsei University·Phase 2·NCT05436990·14 enrolled

First Line Therapy1 trial

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Recruiting·YYuankai Shi·Phase 2·NCT04857164·150 enrolled

Renal Cell Cancer1 trial

A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02212730·10 enrolled

Relapsed/Refractory1 trial

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Withdrawn·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT04279938

Trial1 trial

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

Completed·AAetion, Inc.··NCT05908799·1,854 enrolled

Gastroesophageal Junction Cancer1 trial

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Not yet recruiting·Xxiaohua li·Phase 3·NCT06411171·36 enrolled

PD-1 Inhibitor1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Recruiting·PPhanes Therapeutics·Phase 1/2·NCT05431270·40 enrolled

Merkel Cell Carcinoma1 trial

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Not yet recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT06086288·35 enrolled

Cancer1 trial

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

Completed·CCytovation AS·Phase 1/2·NCT04260529·60 enrolled

Dendritic Cell1 trial

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04571632·36 enrolled

Relapsed/Refractory Hematological Malignancies1 trial

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05005442·192 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06041802·19 enrolled

Newly Diagnosed1 trial

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02845297·67 enrolled

Multiple Myeloma1 trial

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03506360·13 enrolled

Ablation1 trial

Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

Completed·SSun Yat-sen University·Phase 2·NCT03939975·50 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Active, not recruiting·NNational Cancer Center, Korea·Phase 2·NCT05036434·30 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Platinum-resistant1 trial

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Unknown status·UUniversity College, London·Phase 2·NCT03430700·28 enrolled

Thyroid Cancer1 trial

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Recruiting·SSaint Petersburg State University, Russia·Phase 2·NCT06374602·20 enrolled

Hematologic Malignancies1 trial

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06395090

Clear Cell Adenocarcinoma1 trial

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04699071·10 enrolled

Immunochemotherapy1 trial

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Recruiting·HHunan Province Tumor Hospital·Phase 3·NCT05549037·210 enrolled

Locally-advanced Rectal Cancer1 trial

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02921256·363 enrolled

Advanced Cancer1 trial

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Unspecified2 trials

International Multicentric Study ARON-1

Recruiting·HHospital of Macerata··NCT05287464·1,220 enrolled

First in Human Study of T3P-Y058-739 (T3P)

Recruiting·TT3 Pharmaceuticals AG·Phase 1/2·NCT05120596·100 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 4, 2014

Keytruda

BLA 125514

Sep 4, 2014

KEYTRUDA

BLA BLA125514

Sources

References

[1]
ClinicalTrials.gov — 2269 trial records for Pembrolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Keytruda drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pembrolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pembrolizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 125514). U.S. Food & Drug Administration.
[6]
PubMed — 5 publications indexed for Pembrolizumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Merck & Co.

Key Publications[6]

Pembrolizumab Adjuvant Therapy in Resected Stage IIB/IIC Melanoma

LancetMay 22, 2023DOI: 10.1016/S0140-6736(23)00929-2

Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer

N Engl J MedAug 25, 2022DOI: 10.1056/NEJMoa2206594

Neoadjuvant Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2200181

Pembrolizumab in Microsatellite Instability-High Colorectal Cancer

N Engl J MedAug 26, 2021DOI: 10.1056/NEJMoa2107519

Five-Year Survival Outcomes With Pembrolizumab in Advanced NSCLC: KEYNOTE-024

J Clin OncolFeb 22, 2021DOI: 10.1200/JCO.20.03071